Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572034 | 0.99 | MEN1 (0.58) | MEN1KMT2ATDP1NLRP3 | |
| SCHEMBL26975351 | 0.87 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL26975364 | 0.87 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL26975353 | 0.86 | NLRP3 (0.51) | NLRP3 | |
| SCHEMBL26975376 | 0.86 | NLRP3 (0.51) | NLRP3 | |
| SCHEMBL26975371 | 0.86 | NLRP3 (0.51) | NLRP3 | |
| SCHEMBL26975378 | 0.86 | GAA (0.56) | MEN1KMT2ATDP1NLRP3 | |
| SCHEMBL26975355 | 0.85 | MEN1 (0.52) | MEN1KMT2ATDP1 | |
| SCHEMBL22460320 | 0.85 | GAA (0.52) | MEN1KMT2ATDP1NLRP3 | |
| SCHEMBL22460322 | 0.85 | GAA (0.52) | MEN1KMT2ATDP1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| EP-0556322-B1 | AMINOSULFONYL UREA ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1996-06-12 | — | — | EP | claimed |
| EP-0556322-A1 | AMINOSULFONYL UREA ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1993-08-25 | — | — | EP | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | MEN1 3157/4885KMT2A 1326/4885TDP1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.